Lithuania

Lithuania has a small but clearly defined psychedelic- and ketamine-adjacent clinical research footprint, with linked trial activity focused on esketamine and placebo in treatment-resistant depression and major depressive disorder. The country's access environment is conservative: most classical psychedelics remain controlled and are not authorised for routine medical use outside approved research, while ketamine is used within standard medical practice and in some private psychiatric settings.

Ask Blossom about this country

Data updated July 15, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inLithuania.

1
The country brief is best read as a ketamine/esketamine-access market, not a classical-psychedelic access market.
2
The trial footprint is small and currently inactive, which is consistent with limited local psychedelic clinical infrastructure.
3
Academic and hospital-based psychiatric services appear to be the most relevant institutions for any future controlled research activity.
4
The presence of a registered esketamine product provides a concrete, regulated pathway for specialist treatment, but not evidence of broad public access.
5
No linked stakeholders or events suggests the ecosystem is still thinly mapped and likely dependent on a small number of institutions.

Research and Access Snapshot

Blossom currently tracks 4 psychedelic clinical trials connected to Lithuania.

Active trials: 0
Total trials: 4
Stakeholders: 1
Events: 0

Top Compounds

Esketamine(4)

Medical Access

Most classical psychedelics (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, mescaline, 2C-X, ayahuasca) are controlled and not authorised for medical use in Lithuania outside of approved research. Ketamine is an established medical anaesthetic used in hospitals and is used off-label in private clinics for depression; esketamine (Spravato) is registered in Lithuania but routine public reimbursement appears limited and treatment is typically delivered under specialist supervision or via private providers/clinics.

View trials→View stakeholders→Open access guide→

Research Landscape

What the 4 registered trials connected to Lithuania look like when you line them up. Counts come from Blossom’s trial records as of July 2026.

What's live right now, and what stopped?

Sourced

Registry status of all 4 Lithuania trials Blossom tracks. Orange marks trials recruiting or opening.

Completed: 4100%

Browse trials →

Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.

Regulatory Status

Lithuania's regulatory position appears restrictive for classical psychedelics and comparatively permissive only for medicines already authorised or used within normal psychiatric/anaesthetic practice. Official sources show Spravato (esketamine) is registered as a prescription psychotropic medicine in Lithuania, while the general narcotics/psychotropics control framework remains in force; however, routine public access pathways and reimbursement for depression are not clearly established in the sources reviewed, so those details should be treated cautiously.